AFP and neoplasm: We also found that the combination therapy was not beneficial in patients with M1 along with a tumor size of 2–3 cm, one recurrent tumor, or AFP ≤400 μg/L, probably because sorafenib was unable to be taken full advantage in this subpopulation.